热门资讯> 正文

Ascendis Pharma在收购猜测中上涨

2026-01-23 00:47

Ascendis制药(ASND) 0

Ascendis Pharma (ASND) gained 7.5% amid some takeover speculation.
There's talk that a Switzerland-based pharma company and another European firm are eyeing Ascendis (ASND), according to traders, who cited a Betaville "uncooked" alert that was circulating on Thursday.
Betaville first reported last month that the Danish pharmaceutical firm may have attracted takeover interest.
Ascendis (ASND) has a market cap of $13.3 billion.

More on Ascendis Pharma

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia - Slideshow
Ascendis dwarfism drug candidate review extended by FDA
Ascendis Pharma GAAP EPS of - €1.00, revenue of €213.63M

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。